A list of biomarkers currently used in clinics for assisting early diagnosis of prostate cancer has been compiled [203]; however, prostate cancer is heterogeneous with many phenotype variations, and the search for more reliable biomarkers is ongoing as, for example, the presence of TMPRSS2-ERG fusion gene was reported to indicate a more aggressive prostate cancer phenotype [206]. This evidence concerns the gene ERG and Familial prostate cancer.